Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyAsciminib for the Treatment of Patients w. Chronic Myeloid Leukemia

In this Q&A with Dr. Jorge Cortes, the Director of the Georgia Cancer Center, the drug asciminib is discussed based on its utility as a third-generation TKI as well as its favorable, unique characteristics. Early data has shown promising results with few adverse events, possibly illuminating the drug as a potential first-in-class agent.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form